



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad – 500 081, Telangana, INDIA.

Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com

CIN: L24110TG1991PLC012471

Dated August 26, 2022

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Update on GPI facility

Dear Sir,

This is with respect to our communication dated July 23, 2022, regarding the US FDA inspection of Granules Pharmaceuticals, Inc. (GPI), a wholly-owned foreign subsidiary of the Company located in Chantilly, Virginia, USA and issuance of Form 483 with 6 observations.

We now wish to inform you that the GPI has received a communication from the US FDA indicating the inspection classification as “Voluntary Action Indicated.” (VAI). The VAI inspection classification indicates that the US FDA will not take or recommend regulatory or enforcement action because the observations do not meet the threshold for action at this time.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

For GRANULES INDIA LIMITED



**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**